XML 250 R177.htm IDEA: XBRL DOCUMENT v3.25.1
Reportable segments - Comprehensive Income by Reportable Segment (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Disclosure of operating segments [line items]      
Revenue $ 4,528,761 $ 7,467,490 $ 10,710,578
Cost of sales (3,201,654) (4,392,436) (4,973,953)
Gross profit 1,327,107 3,075,054 5,736,625
Other incomes by function 32,229 40,557 9,854
Administrative expenses (185,959) (175,765) (142,644)
Other expenses by function (104,698) (93,400) (75,971)
Impairment of gains and review of impairment losses (impairment losses) determined in accordance with IFRS 9 (639) 202 3,369
Other losses (2,142) (2,254) 117
Financial income 103,642 122,726 47,038
Finance costs (197,544) (138,402) (86,651)
Interest in the income of associates and joint ventures accounted for by the equity method 11,025 593 20,159
Exchange differences (8,607) (22,293) (25,400)
Income before taxes 974,414 2,807,018 5,486,496
Income tax benefit (expense) (282,573) (1,876,751) (1,572,212)
Net income 691,841 930,267 3,914,284
Specialty plant nutrients      
Disclosure of operating segments [line items]      
Revenue 941,940 913,912 1,172,334
Cost of sales (775,152) (691,509) (722,261)
Gross profit 166,788 222,403 450,073
Other incomes by function 0 0 0
Administrative expenses 0 0 0
Other expenses by function 0 0 0
Impairment of gains and review of impairment losses (impairment losses) determined in accordance with IFRS 9 0 0 0
Other losses 0 0 0
Financial income 0 0 0
Finance costs 0 0 0
Interest in the income of associates and joint ventures accounted for by the equity method 0 0 0
Exchange differences 0 0 0
Income before taxes 166,788 222,403 450,073
Income tax benefit (expense) 0 0 0
Net income 166,788 222,403 450,073
Iodine and its derivatives      
Disclosure of operating segments [line items]      
Revenue 968,312 892,151 754,339
Cost of sales (444,904) (355,717) (282,100)
Gross profit 523,408 536,434 472,239
Other incomes by function 0 0 0
Administrative expenses 0 0 0
Other expenses by function 0 0 0
Impairment of gains and review of impairment losses (impairment losses) determined in accordance with IFRS 9 0 0 0
Other losses 0 0 0
Financial income 0 0 0
Finance costs 0 0 0
Interest in the income of associates and joint ventures accounted for by the equity method 0 0 0
Exchange differences 0 0 0
Income before taxes 523,408 536,434 472,239
Income tax benefit (expense) 0 0 0
Net income 523,408 536,434 472,239
Lithium and its derivatives      
Disclosure of operating segments [line items]      
Revenue 2,241,250 5,180,114 8,152,939
Cost of sales (1,666,328) (2,955,669) (3,636,852)
Gross profit 574,922 2,224,445 4,516,087
Other incomes by function 0 0 0
Administrative expenses 0 0 0
Other expenses by function 0 0 0
Impairment of gains and review of impairment losses (impairment losses) determined in accordance with IFRS 9 0 0 0
Other losses 0 0 0
Financial income 0 0 0
Finance costs 0 0 0
Interest in the income of associates and joint ventures accounted for by the equity method 0 0 0
Exchange differences 0 0 0
Income before taxes 574,922 2,224,445 4,516,087
Income tax benefit (expense) 0 0 0
Net income 574,922 2,224,445 4,516,087
Industrial chemicals      
Disclosure of operating segments [line items]      
Revenue 78,155 175,223 165,200
Cost of sales (47,453) (141,351) (112,247)
Gross profit 30,702 33,872 52,953
Other incomes by function 0 0 0
Administrative expenses 0 0 0
Other expenses by function 0 0 0
Impairment of gains and review of impairment losses (impairment losses) determined in accordance with IFRS 9 0 0 0
Other losses 0 0 0
Financial income 0 0 0
Finance costs 0 0 0
Interest in the income of associates and joint ventures accounted for by the equity method 0 0 0
Exchange differences 0 0 0
Income before taxes 30,702 33,872 52,953
Income tax benefit (expense) 0 0 0
Net income 30,702 33,872 52,953
Potassium      
Disclosure of operating segments [line items]      
Revenue 270,783 279,050 437,180
Cost of sales (236,390) (219,597) (193,581)
Gross profit 34,393 59,453 243,599
Other incomes by function 0 0 0
Administrative expenses 0 0 0
Other expenses by function 0 0 0
Impairment of gains and review of impairment losses (impairment losses) determined in accordance with IFRS 9 0 0 0
Other losses 0 0 0
Financial income 0 0 0
Finance costs 0 0 0
Interest in the income of associates and joint ventures accounted for by the equity method 0 0 0
Exchange differences 0 0 0
Income before taxes 34,393 59,453 243,599
Income tax benefit (expense) 0 0 0
Net income 34,393 59,453 243,599
Other products and services      
Disclosure of operating segments [line items]      
Revenue 28,321 27,040 28,586
Cost of sales (31,427) (28,593) (26,912)
Gross profit (3,106) (1,553) 1,674
Other incomes by function 0 0 0
Administrative expenses 0 0 0
Other expenses by function 0 0 0
Impairment of gains and review of impairment losses (impairment losses) determined in accordance with IFRS 9 0 0 0
Other losses 0 0 0
Financial income 0 0 0
Finance costs 0 0 0
Interest in the income of associates and joint ventures accounted for by the equity method 0 0 0
Exchange differences 0 0 0
Income before taxes (3,106) (1,553) 1,674
Income tax benefit (expense) 0 0 0
Net income (3,106) (1,553) 1,674
Corporate Unit      
Disclosure of operating segments [line items]      
Revenue 0 0 0
Cost of sales 0 0 0
Gross profit 0 0 0
Other incomes by function 32,229 40,557 9,854
Administrative expenses (185,959) (175,765) (142,644)
Other expenses by function (104,698) (93,400) (75,971)
Impairment of gains and review of impairment losses (impairment losses) determined in accordance with IFRS 9 (639) 202 3,369
Other losses (2,142) (2,254) 117
Financial income 103,642 122,726 47,038
Finance costs (197,544) (138,402) (86,651)
Interest in the income of associates and joint ventures accounted for by the equity method 11,025 593 20,159
Exchange differences (8,607) (22,293) (25,400)
Income before taxes (352,693) (268,036) (250,129)
Income tax benefit (expense) (282,573) (1,876,751) (1,572,212)
Net income $ (635,266) $ (2,144,787) $ (1,822,341)